Argenx and genmab enter partnership to advance antibody therapies in immunology and oncology

Amsterdam, the netherlands – 0 4 / 17 /2023 argenx se (euronext & nasdaq: argx) and genmab a/s (nasdaq: gmab) announced today that argenx and genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. the multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address unmet patient needs in immunology and cancer.
ARGX Ratings Summary
ARGX Quant Ranking